1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended March 31, 2021.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended June 30, 2021.
Refer to Part I, Item 2.
−Removed: "Liquidity and Capital Resources" for further details of the share repurchase program.
+Added: "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
1 unchanged sentence
5/1/2021–5/31/2021 185,402 $ 502.22 185,376 $ 937,224,637
+Added: 6/1/2021–6/30/2021 96,748 $ 514.91 95,892 $ 887,866,800
Total 583,099 (a)
1 unchanged sentence
Exhibit Number Description
−Removed: Supply Agreement, dated as of January 12, 2021, by and between Regeneron Pharmaceuticals, Inc.
−Removed: (the "Registrant") and the U.S.
−Removed: Army Contracting Command, New Jersey.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2021 and 2020;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2021 and 2020;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2021 and 2020;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2021 and 2020;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2020;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: * Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
−Removed: May 6, 2021 By:
+Added: August 5, 2021 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.